Industries

生物制药特许权

Toutes les analyses de 生物制药特许权 — 1 analyses.

50/100 58Buffett Hold Royalty Pharma: $3.254bn of Portfolio Receipts and 48% Deal Share Meet a 24% Expiry Wall by 2030 and a $58.41 Price That Already Pays for the Platform Royalty Pharma is a specialty-finance platform whose loan book is denominated in molecules: it buys contractual percentages of other companies' drug sales, funds late-stage development in exchange for synthetic royalties, and collects near the top of the income statement while somebody else carries the commercial cost. 2025 Portfolio Receipts were $3.254bn against only $288m of cash operating and professional costs, and the company sourced 48% of announced biopharma-royalty transaction value over 2020-2025, but roughly 24% of 2025 Royalty Receipts sits on products whose royalty duration substantially ends by 2030, and hitting the $4.7bn 2030 target needs $2.0-2.5bn of deployment every year. Rating Hold: at $58.41 the shares are near 11.6 times estimated 2026 Portfolio Cash Flow but 19-23 times owner earnings once $1.1-1.4bn of replacement deployment is charged as economic maintenance, above the $46-50 conservative value, so the report waits for $36-40 before committing new capital. Royalty Pharma plcRPRX · États-Unis生物制药特许权20 septembre 2026